You are here

Fosinopril Sodium Tablets Approved by FDA

Jerusalem, Israel, November 25, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval of the company's ANDA for Fosinopril Sodium Tablets, 10 mg, 20 mg and 40 mg.

This approval follows an October 27, 2003 decision by the U.S. District Court for the Southern District of New York granting judgment in favor of Teva on the issue of non-infringement with regard to Bristol-Myers Squibb's Monopril® Patent No. 5,006,344.

As the first company to file an ANDA with a Paragraph IV patent certification for this product, Teva became eligible for 180 days marketing exclusivity for this product from the date of last month's court decision.

Fosinopril Sodium Tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's Monopril® Tablets. This product is indicated for the treatment of hypertension and management of congestive heart failure. Annual sales of the brand product through June 2003 were $267 million.

Source: Teva Pharmaceutical Industries Ltd.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress